Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building strategies and community education programs.

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Nirsevimab Reduced Hospitalizations for Infants With RSV — Monoclonal antibody is highly effective, but in short supply by Katherine Kahn, Staff Writer, MedPage Today December 27, 2023 ...

According to the CDC’s announcement, there is a limited supply of nirsevimab from the manufacturer for the 2023-2024 RSV season, with prefilled syringes of 100-mg doses in especially short supply.